AbbVie is reported to be nearing an approximately $11 billion deal for Apogee, signaling continued consolidation in biopharma. The move would extend AbbVie’s footprint by adding Apogee’s development assets and/or capabilities, depending on the final terms. Because deal-specific financial and clinical details were not provided in the snippet, investors typically watch for whether the transaction includes late-stage candidates, platform technology, or near-term commercial products. For industry participants, an $11B scale bid would underscore the appetite for larger platform acquisitions and a willingness to pay up for differentiated pipelines.